A frequent Gene Polymorphism Affecting the Heart-rate Response to Carvedilol

Eschenhagen, Thomas

doi:10.2217/pgs.12.198

Cited by 3 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32,33 Importantly, a frequent ADRB1 polymorphism affecting the heartrate response to carvedilol has been identified. 34 The present study demonstrated that the ADRB1 mutation had a significant clinical effect on b-blocker therapy. This is consistent with reports that mutations in the ADRB1 gene cause decreased b 1 -adrenoceptor sensitivity, 26,27 and is in good agreement with other findings in both healthy individuals and essential hypertension patients.…”

Section: 2supporting

confidence: 53%

Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension

Deng

et al. 2015

J Int Med Res

View full text Add to dashboard Cite

Objective: To investigate the associations between b 1 -adrenergic receptor (ADRB1) and cytochrome P450 2D6 (CYP2D6) gene polymorphisms and b-blocker treatment outcomes in patients with hypertension. Methods: Chinese patients with essential hypertension were treated with the b-blocker metoprolol and followed up for 12 weeks. xTAG Õ liquid-chip technology was used for CYP2D6 100 C > T and ADRB1 1165G > C genotyping. Associations between gene polymorphisms and antihypertensive therapy outcomes were assessed by generalized linear model fitting. A decrease of ! 10 mmHg in systolic blood pressure indicated an effective treatment outcome. Results: A total of 93 patients were included in the study. Mutant allele frequencies of 61.29% and 58.60% were obtained for ADRB1 and CYP2D6, respectively. There was no significant interaction between the effects of ADRB1 and CYP2D6 gene polymorphisms on treatment outcome. Patients homozygous for the mutant ADRB1 genotype (CC) had better treatment outcomes than those heterozygous for the mutation (GC). Interestingly, b-blocker treatment duration was an independent factor associated with treatment outcome. Conclusions: The ADRB1 1165G > C gene polymorphism and b-blocker treatment duration are independent factors associated with b-blocker treatment outcome. These findings suggest that the selection of antihypertensive therapy should take into consideration the patient's genotype.

show abstract

Section: 2supporting

confidence: 53%

Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension

Deng

et al. 2015

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…1 Compared with conventional b-blockers, carvedilol maintains cardiac output and reduces blood pressure by decreasing vascular resistance. [5][6][7][8][9][10] However, the association of polymorphisms in ADRB1 or ADRB2 and carvedilol responsiveness in antihypertensive therapy has not been reported. 3,4 Two major single nucleotide polymorphisms (SNPs) are known in the ADRB1 gene (Ser49Gly and Arg389Gly) and 2 major SNPs in the ADRB2 gene (Arg16Gly and Gln27Glu).…”

Section: Introductionmentioning

confidence: 99%

Association of Common Polymorphisms in β1-adrenergic Receptor With Antihypertensive Response to Carvedilol

Wang

Xü

et al. 2014

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

show abstract

“…Some of these common SNPs are increasingly associated with variable ββ responses: bucindolol – potential genetic due frequency of [52, 76], carvedilol [77], atenolol [78] and metoprolol [25]. It is interesting to note the observations that African Americans may have a poorer responses to ββ and HF outcomes also correlates with may findings of greater prevalence of Arg389 alone and in association with ADRA2C [79] and Leu41Gln variant in GRK5 [49, 80].…”

Section: Genetics In Indigenous Australiansmentioning

confidence: 99%

Contextualizing Genetics for Regional Heart Failure Care

Iyngkaran

Thomas²,

Johnson³

et al. 2016

CCR

View full text Add to dashboard Cite

Congestive heart failure (CHF) is a chronic and often devastating cardiovascular disorder with no cure. There has been much advancement in the last two decades that has seen improvements in morbidity and mortality. Clinicians have also noted variations in the responses to therapies. More detailed observations also point to clusters of diseases, phenotypic groupings, unusual severity and the rates at which CHF occurs. Medical genetics is playing an increasingly important role in answering some of these observations. This developing field in many respects provides more information than is currently clinically applicable. This includes making sense of the established single gene mutations or uncommon private mutations. In this thematic series which discusses the many factors that could be relevant for CHF care, once established treatments are available in the communities; this section addresses a contextual role for medical genetics.

show abstract

A frequent Gene Polymorphism Affecting the Heart-rate Response to Carvedilol

Cited by 3 publications

References 21 publications

Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension

Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension

Association of Common Polymorphisms in β1-adrenergic Receptor With Antihypertensive Response to Carvedilol

Contextualizing Genetics for Regional Heart Failure Care

Contact Info

Product

Resources

About